Mnemosyne Pharmaceuticals Lands $250,000 Seed Financing Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=c0ce2576-9291-4953-a4d8-60596d01fe6b&Preview=1
Date
11/15/2011
Company Name
Mnemosyne Pharmaceuticals
Mailing Address
Undisclosed Providence, RI 02902
Company Description
The company is a Providence-based drug discovery venture aiming to develop small molecule therapeutics to treat schizophrenia and other cognitive and neuropsychiatric disorders.
Website
Undisclosed
Transaction Type
Venture Equity
Transaction Amount
$250,000
Transaction Round
Seed
Proceeds Purposes
Mnemosyne is currently developing a research platform targeting NMDA receptor function, one of the most impactful signaling mechanisms in the brain. The company is aiming to develop small molecule therapeutics to treat schizophrenia and other cognitive and neuropsychiatric disorders.
M&A Terms
Venture Investor
Slater Technology Fund